Dr. Bader has worked in the field of mental health and addiction for more than 18 years. She graduated from the University of North Texas in 2007 with a PhD in counseling psychology and specialization in sport psychology, and completed her postdoctoral fellowship in Chemical Dependency at the University of Oklahoma Health Sciences Center. She is a Licensed Psychologist and Licensed Addiction Counselor, in addition she also a Certified Mental Performance Consultant working with elite athletes and teams.
Dr. Bader has worked in a variety of treatment settings including residential, outpatient, private practice, and Native American health care. She spends time in the sport environment in collegiate athletic departments, working with professional teams, and Olympic athletes. She currently compliments the multi-disciplinary team at Women’s Recovery by serving as the Chief Clinical Officer, advancing treatment for women. In addition, she maintains a private practice offering counseling, consultation, educational presentations, and sport psychology services. She authored a chapter in the evidenced based book, Cannabis in Medicine. She serves on the Speakers Bureau for the National Marijuana Initiative as a subject matter expert on emerging research, addiction and treatment.
Many people have heard about the risk of your BRAIN on drugs, but what about your SKIN on drugs? Your skin, your epidermis is the largest organ of your body and is about 20 square feet. Dr. Antley is a dermatopathologist and talks to High Truth about whether marijuana products can help acne or harmful to the skin. Catherine Antley, M.D. Catherine Antley, M.D. graduated from the University of North Carolina School of Medicine, completed her residency in anatomic and clinical pathology at Duke University Medical Center and fellowship in dermatopathology at the University of Arkansas for Medical Sciences. She is board certified in Anatomic and Clinical Pathology and in Dermatopathology and is a Fellow of the American Society of Dermatopathology. For 20 years she has served as laboratory director of Vermont Dermatopathology, a woman owned, independent dermatopathology lab serving VT, NY, and NH. She has a strong interest in public health and prevention and exploring the impact of policy on addiction and health care costs. She has co-authored a number of Vermont Medical Society resolutions on cannabis and recently organized and led a delegation of 10 Vermonters to Iceland to learn about their 20 year history bringing down the country’s high addiction rates using their successful, science based prevention model. She recently contributed a chapter “Cannabis in Dermatology” to the textbook “Cannabis in Medicine, an Evidence Based Approach” edited by Dr. Ken Finn and published by Springer Nature. Cannabis in Medicine: An Evidence Based Review ...
Brian Hurley, MD, MBA, DFASAM is an addiction physician and the Medical Director of the Division of Substance Abuse Prevention and Control in the Los Angeles County Department of Public Health. He is the President-Elect of the American Society of Addiction Medicine and gives presentations around the world regarding addiction medicine. He co-chairs the SafeMedLA Medications for Addiction Treatment Action Team and is the Clinical Director of the Treatment Starts Here program through the Center for Clinical Innovation, focused on increasing the delivery of medications for addiction treatment in California’s community health centers. He is a senior researcher at the Friends Research Institute and is a primary investigator on a Tobacco Related Disease Prevention Program-funded project integrating smoking cessation services into community mental health centers and patient-centered medical homes and is the grant lead for three Medications for Addiction Treatment Access Points projects funded by the Sierra Health Foundation supporting access to medications for addiction treatment across Los Angeles County. He is also a co-investigator for several Rand Corporation projects evaluating the integration of substance use disorder and mental health treatment within community health settings. He also serves on the American Board of Psychiatry and Neurology’s Addiction Psychiatry Examination Writing Committee. Brian completed the Robert Wood Johnson Foundation Clinical Scholars Program at the University of California, Los Angeles (UCLA) and is an alumnus of the Massachusetts General Hospital and McLean Hospital Psychiatry Residency Training Program and the New York University Addiction Psychiatry Fellowship. On the Episode we talk about Emergency Department Drug Surviellance. This shows interesting data from 5 different hospitals across the country. ...
The pain of stigma comes out as Gary Mendell, CEO of Shatterproof talks about his son Brian. It is now his life mission to make a difference, and Shatterproof is doing just that. Shatterproof, under Gary’s leadership shows that words matter. For example, addiction is not just a chronic disease of the brain – it is a treatable chronic disease of the brain. Treatment gives hope. But how do we balance stigma as a stool for prevention – “don’t smoke” “drugs are bad” while we eliminate the stigma against a human being with a problem? Listen to Dr. Lev and Gary discuss this issue. Gary Mendell, Founder and CEO, Shatterproof Gary Mendell is the founder and CEO of Shatterproof, a national nonprofit dedicated to reversing the addiction crisis in the United States. After losing his son Brian to addiction in 2011, Gary founded Shatterproof to spare other families the tragedy his had suffered. Since founding Shatterproof, Mr. Mendell has been recognized as a national leader in the addiction space, working to transform how opioid and substance use disorders are treated. His priorities include advocating for state and federal policy change, ending the harmful stigma of addiction, and supporting and educating our communities. Mr. Mendell has testified in front of the President’s Commission on Combating Drug Addiction and the Opioid Crisis and his opinions are frequently reflected in the media. He also serves on the Executive Advisory Board of the University of Pennsylvania’s Leonard Davis Institute of Health Economics, is a member of the National Quality Forum’s Technical Expert Panel for Opioid and Opioid Use ...
